Breaking
🌏 NMPA
NMPA Priority Review Granted to AI Diagnostic Tool for Early Cancer Detection
NewsOncologyApr 13, 2026

NMPA Priority Review Granted to AI Diagnostic Tool for Early Cancer Detection

The NMPA has granted priority review to an innovative AI diagnostic tool designed for early cancer detection, promising to revolutionize patient outcomes.

Dr. Yuki Tanaka
PMDA approves AI-driven platform: What You Need to Know
NewsOncologyApr 13, 2026

PMDA approves AI-driven platform: What You Need to Know

The PMDA has approved a groundbreaking AI-driven platform, revolutionizing drug development and safety protocols in the pharmaceutical industry.

Dr. Yuki Tanaka
AI in Drug Discovery Japan: What You Need to Know
AnalysisOncologyApr 12, 2026

AI in Drug Discovery Japan: What You Need to Know

Discover the impact of AI on drug discovery in Japan, highlighting advancements in treatments such as Ozanimod for multiple sclerosis and their implications.

Dr. Yuki Tanaka
NMPA Data Integrity: What Pharmaceutical Manufacturers Must Know
NewsApr 11, 2026

NMPA Data Integrity: What Pharmaceutical Manufacturers Must Know

Understanding NMPA data integrity is crucial for pharmaceutical manufacturers to ensure compliance and maintain trust in drug safety and efficacy.

Dr. Yuki Tanaka
AI-Powered Clinical Trial Matching: Accelerating Drug Development in China
NewsClinical TrialsApr 10, 2026

AI-Powered Clinical Trial Matching: Accelerating Drug Development in China

AI-driven clinical trial matching is revolutionizing drug development in China, streamlining processes for new therapies and improving patient recruitment.

Dr. Yuki Tanaka
Telemedicine in APAC: Opportunities & Challenges for Pharma Firms
NewsDigital HealthApr 10, 2026

Telemedicine in APAC: Opportunities & Challenges for Pharma Firms

Telemedicine offers APAC pharma firms unique opportunities and challenges, reshaping patient access to medications like Lipitor for effective cholesterol control.

Dr. Yuki Tanaka